hematopoietic system
• in tamoxifen-treated mice
|
• in tamoxifen-treated mice
|
• in the spleen of tamoxifen-treated mice
|
• in tamoxifen-treated mice
|
• tamoxifen-treated mice exhibit disturbed cell distribution with pronounced dysplasia and disrupted maturation in the erythroid, megakaryocytic and granulocytic lineages compared with control mice
• bone marrow from tamoxifen-treated mice exhibit reduced formation of colony forming units compared with control mice
• however, tamoxifen-treated mice exhibit normal numbers of hematopoietic stem cells
|
• decreased granulocyte-macrophage progenitors and macrophage colony numbers from bone marrow of tamoxifen-treated mice
|
• abnormal nuclear lobation and atypical mitosis in tamoxifen-treated mice
|
• in tamoxifen-treated mice
|
• in tamoxifen-treated mice
|
• in tamoxifen-treated mice
|
• in tamoxifen-treated mice
|
• dysplastic granulocytes with nuclear hyposegmentation in tamoxifen-treated mice
|
• in tamoxifen-treated mice
|
• in the spleen of tamoxifen-treated mice
|
• relative in tamoxifen-treated mice
|
• impaired migration in hematopoietic stem and progenitor cells of tamoxifen-treated mice
|
cellular
• increased chromosomal double-strand breaks and numerical and structural chromosomal aberrations 2 weeks after tamoxifen-treatment
|
growth/size/body
weight loss
(
J:196401
)
• in tamoxifen-treated mice
|
• in tamoxifen-treated mice
|
• in tamoxifen-treated mice
|
skeleton
• anemic appearance of the bones in tamoxifen-treated mice
|
immune system
• in tamoxifen-treated mice
|
• in tamoxifen-treated mice
|
• dysplastic granulocytes with nuclear hyposegmentation in tamoxifen-treated mice
|
• in the spleen of tamoxifen-treated mice
|
• relative in tamoxifen-treated mice
|